Black and Hispanic/Latino patients with food allergies are less apt to recognize anaphylaxis and have more limited EAI access than White patients.

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.

Nearly 1 in 4 Americans believe the US health care system is in crisis, and high costs are the top reason why.

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

President Donald Trump signed an executive order that could make it easier for scientists to study cannabis for medical use.

The FDA is weighing a change that could make warning labels on dietary supplements appear less often on packaging.

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

FDA approves Rybrevant Faspro, a subcutaneous amivantamab formulation, for all indications previously held by the intravenous formulation.

Traditional Chinese medicine (TCM) pediatric tuina may be safe and effective as supplementary therapy in children with severe pneumonia.

The HHS has ended several health grants to one of the nation’s largest pediatricians’ groups, a move the organization says could hurt children and families.

Influenza season is getting an early start in New York City, with doctors reporting a sharp jump in cases weeks sooner than normal.